A5061275603- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- Kruppel-like factors research
- Chronic Myeloid Leukemia Treatments
- Eosinophilic Disorders and Syndromes
- Hemoglobinopathies and Related Disorders
- Erythrocyte Function and Pathophysiology
- Multiple Myeloma Research and Treatments
- Chronic Lymphocytic Leukemia Research
- Blood disorders and treatments
- Platelet Disorders and Treatments
- Cytokine Signaling Pathways and Interactions
- Renal Diseases and Glomerulopathies
- Diabetes Treatment and Management
- Cancer Genomics and Diagnostics
- Immune Cell Function and Interaction
- Iron Metabolism and Disorders
- Cancer-related molecular mechanisms research
- Bone and Joint Diseases
- Bone health and treatments
- HER2/EGFR in Cancer Research
- Metabolism, Diabetes, and Cancer
- Lymphoma Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Cardiac tumors and thrombi
Hôpital Maisonneuve-Rosemont
2016-2025
Université de Montréal
2016-2025
MPB Technologies & Communications (Canada)
2023-2025
Quebec - Clinical Research Organization in Cancer
2020-2022
Mayo Clinic in Arizona
2018-2021
Hôpital du Sacré-Cœur de Montréal
2020
Mayo Clinic
2017-2018
WinnMed
2018
Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal
2017
Centre Hospitalier Universitaire Sainte-Justine
2017
Survival prediction in essential thrombocythaemia (ET) and polycythaemia vera (PV) is currently based on clinically-derived variables; we examined the possibility of integrating genetic information for predicting survival. To this end, 906 molecularly-annotated patients (416 Mayo Clinic; 490 University Florence, Italy), including 502 ET 404 PV, were recruited. Multivariable analysis identified spliceosome mutations to adversely affect overall (SF3B1, SRSF2 PV) myelofibrosis-free (U2AF1,...
Abstract The 2013 discovery of calreticulin ( CALR ) mutations in myeloproliferative neoplasms was attended by their association with longer survival primary myelofibrosis (PMF). Subsequent studies have suggested prognostic distinction between type 1/like and 2/like detrimental effect from triple‐negative mutational status. Among 709 Mayo Clinic patients PMF, 467 (66%) harbored JAK2 , 112 (16%) 1/like, 24 (3.4%) 2/like, 38 (5.4%) MPL 68 (10%) were triple‐negative. Survival compared to (HR...
JAK2 unmutated or non-polycythemia vera (PV) erythrocytosis encompasses a heterogenous spectrum of hereditary and acquired entities.Foremost in the evaluation is exclusion PV through (inclusive exons 12-15) mutation screening. Initial assessment should also include gathering previous records on hematocrit (Hct) hemoglobin (Hgb) levels, order to streamline diagnostic process by first distinguishing longstanding from erythrocytosis; subsequent subcategorization facilitated serum erythropoietin...
Abstract Between 1967 and 2017, 361 patients with myeloproliferative neoplasms (MPN), age ≤ 40 years, were seen at our institution, constituting 12% of all MPN ( n = 3023) during the same time period; disease‐specific incidences in polycythemia vera (PV; 79), 20% essential thrombocythemia (ET; 219) 5% primary myelofibrosis (PMF; 63). Compared to their older counterparts, younger more likely present low risk disease P < .001) display female preponderance ET .04), lower incidence arterial...
Abstract Venetoclax (Ven) combined with a hypomethylating agent (HMA) has now emerged as an effective treatment regimen for acute myeloid leukemia, in both de novo and relapsed/refractory setting. The current multicenter study retrospectively examined Ven + HMA outcome among 32 patients (median age 69 years; 59% males) blast‐phase myeloproliferative neoplasm (MPN‐BP). Pre‐leukemic phenotype included essential thrombocythemia (ET)/post‐ET myelofibrosis (34%), polycythemia vera (PV)/post‐PV...
We examined the individual prognostic contribution of absolute neutrophil (ANC), lymphocyte (ALC), and monocyte (AMC) counts, on overall (OS), leukemia-free (LFS), myelofibrosis-free (MFFS) survival in essential thrombocythemia (ET). Informative cases (N = 598; median age 59 years; females 62%) were retrospectively accrued from a Mayo Clinic database: JAK2 59%, CALR 27%, triple-negative 11%, MPL 3%; international scoring system for ET (IPSET) risk high 21%, intermediate 42%, low 37%; 7%...
Abstract Among 281 patients with essential thrombocythemia and calreticulin (CALR) mutation, we found a variant allele frequency of ≥60% to be associated significantly shortened myelofibrosis-free survival, mostly apparent CALR type-1 type-indeterminate mutations.
Abstract To develop a genetic risk model for primary myelodysplastic syndromes (MDS), we queried the prognostic significance of next‐generation sequencing (NGS)‐derived mutations, in context Mayo cytogenetic stratification, which includes high‐risk (monosomal karyotype; MK), intermediate‐risk (non‐MK, classified as intermediate/poor/very poor, per revised international scoring system; IPSS‐R), and low‐risk (classified good/very good, IPSS‐R). Univariate analysis 300 consecutive patients with...
Chronic neutrophilic leukemia (CNL) is a rare, often aggressive myeloproliferative neoplasm (MPN) defined by persistent mature leukocytosis, bone marrow granulocyte hyperplasia, and frequent hepatosplenomegaly. The 2013 seminal discovery of oncogenic driver mutations in colony-stimulating factor 3 receptor (CSF3R) the majority patients with CNL not only established its molecular pathogenesis but provided diagnostic biomarker rationale for pharmacological targeting.In 2016, World Health...